Government of Canada invests $5.7M in new research network to study deadly blood infections
McMaster University-based network will bring together researchers and patients to tackle sepsis—a leading cause of death in COVID-19
July 23, 2020 – Hamilton, Ontario – Canadian Institutes of Health Research
Sepsis is a life-threatening condition that results from an out-of-control immune response to an infection that may lead to tissue damage, organ failure and death. Children, seniors, those with chronic health conditions like diabetes, cancer or immunodeficiency, and members of certain groups such as Indigenous Peoples, new immigrants to Canada, and those with unstable housing are especially vulnerable to sepsis.
The source of infection in sepsis can be a microbial pathogen such as a virus or bacterium. The new coronavirus that causes COVID-19 is now on the list of pathogens that cause sepsis. Most patients who are critically ill with COVID-19 develop sepsis, which becomes a major threat to their survival.
Today, the Honourable Filomena Tassi, Minister of Labour, on behalf of the Honourable Patty Hajdu, Minister of Health, announced an investment of $5.7 million from the Government of Canada, through the Canadian Institutes of Health Research (CIHR), to support Sepsis Canada, a new national research network that will improve the treatment and recovery of sepsis patients. Sepsis Canada brings together 190 clinicians, scientists, and patients representatives across the country.
Led by Dr. Alison Fox-Robichaud at McMaster University and Dr. François Lamontagne at Université de Sherbrooke, Sepsis Canada will track and study treatments for septic patients, and develop a bank of evidence-based tools to educate the public and health care professionals about how to best prevent, diagnose and manage sepsis. The network will also collect data that will give a true understanding of the burden of sepsis in Canada. A recent global report published in the journal Lancet estimated that 75,000 cases of sepsis occur in Canada every year, likely causing 18,000 deaths.
Given the association between sepsis and severe COVID-19 infection, many members of the network are participating in COVID-19 research projects funded by CIHR and other agencies.
- Dr. Robert Hancock at the University of British Columbia is developing diagnostic tools to predict the severity of disease in patients with COVID-19 and guide the course of treatment.
- Dr. Margaret Herridge at the University of Toronto is part of team that will collect and analyze hospital and ICU admissions data to determine how hospital systems could be better organized to care for patients with COVID-19.
- Dr. Kirsten Fiest at the University of Calgary is leading a team that seeks to understand and manage the effects of COVID-19 restricted visitation policies on the families and healthcare providers of critically ill patients.
- Dr. François Lamontagne at Université de Sherbrooke is leading a clinical trial to determine the effectiveness of vitamin C as a treatment for sepsis, including sepsis in COVID-19 patients.
The results of these projects and others will be shared throughout the network and help improve the treatment of patients with severe COVID-19 infection leading to sepsis.
“The importance of understanding how to track and treat sepsis has never been as important as it is now. We are proud to help bring together this impressive group of clinicians, researchers, and patients from across the country. They will collaborate to produce knowledge that will improve the health of Canadians and contribute to a more sustainable health care system.”
The Honourable Patty Hajdu
Minister of Health
“McMaster University is home to some of Canada’s best researchers. As a researcher and professor at McMaster and a critical care specialist at Hamilton Health Sciences, Dr. Fox-Robichaud has become a scientific leader and passionate advocate for the sepsis community while continuing to provide exceptional care for people living in our community. By working with her colleagues and partners in this new national initiative, she will improve the lives of many Canadians and their families.”
The Honourable Filomena Tassi
Minister of Labour and Member of Parliament for Hamilton West – Ancaster – Dundas
“Sepsis is a serious and complex medical condition that is best addressed using a muti-disciplinary team approach. By bringing together health care workers, researchers, patients and advocates, the CIHR support for Sepsis Canada will help ensure that we find the most effective and enduring approaches to mitigate this critical and long-standing health challenge.”
Dr. Brian Rowe
Scientific Director, CIHR-Institute of Circulatory and Respiratory Health
“Canadians should be aware that sepsis, the life-threatening response to an infection, is a global health issue and never is this more apparent than during the current pandemic. Our team of scientists, knowledge users, patient and family members and partners are prepared to change the story within our country. We will do this by better understanding the epidemiological and financial burden of sepsis in Canada, by understanding and improving the long-term outcomes of sepsis survivors, by creating a culture of sepsis awareness in Canada, by working to assure standardized practices for sepsis surveillance, detection and prevention, by improving the understanding the complex interactions between predisposing conditions, the infections that cause sepsis and the response to those infections and by discovering new evidence-based cost-effective therapies.”
Dr. Alison Fox-Robichaud,
Scientific Director, Sepsis Canada, and Professor, McMaster University
Sepsis is a life threatening health condition. It is a serious challenge for patients and health care providers in Canada and globally.
According to a recent global report published in the journal Lancet, an estimated 75,000 cases of sepsis occur in Canada every year, likely causing 18,000 deaths.
The Government of Canada, through the Canadian Institutes of Health Research, is investing $5.7 million in Sepsis Canada, a new national research network.
Sepsis Canada will improve the identification, prevention, detection and management of sepsis in Canada through coordinated national research activities to generate new knowledge, technical and scientific expertise.
NCT04503096Not yet recruitingConditions: Mild Cognitive Impairment
NCT04503109RecruitingSpinal Cord Stimulation in the Treatment of Chronic, Intractable Pain Using the Nalu™ Neurostimulation SystemConditions: Pain, Chronic; Pain, Intractable; Pain, Back
NCT04503122Not yet recruitingConditions: Paroxysmal Atrial Fibrillation
NCT04503135Not yet recruitingConditions: Central Venous Catheters; Central Venous Catheter Thrombosis; Thrombosis, Venous; Intensive Care Unit
NCT04503148Not yet recruitingConditions: Renal Cell Carcinoma
NCT04503161Not yet recruitingThe Effect of an ASC-seeded Collagen Hydrogel on Cerebrospinal Fluid Leak Rates Following Skull Base SurgeryConditions: CSF Leak
NCT04503174Not yet recruitingConditions: Diabetes Mellitus, Type 1
NCT04503187RecruitingConditions: Stroke; Multiple Sclerosis
NCT04503200Not yet recruitingDouble Guidewire Technique Versus Transpancreatic Precut in Patients With Repetitive Unintentional Cannulation of the Pancreatic Duct.Conditions: Endoscopic Retrograde Cholangiopancreatography; Common Bile Duct Diseases; Transpancreatic Precut; Precut; Double Guidewire
NCT04503213Enrolling by invitationConditions: CSF1R-related Leukoencephalopathy; ALSP; POLD; Hematopoietic Stem Cell Transplantation
Featured Contract Research Organizations
ZM Company is part of the Group of International Drug Safety Contract Research Organizations (CROs), with offices in Canada (ZM), Russia (3M Veritas),...
Lowden International Ltd is a consortium of experienced consultants who specialise in the qaulity management processes of pharmaceutical manufacturing...
Source BioScience Limited
Source BioScience Limited is an international provider of integrated state of the art Laboratory Services and Products. Headquartered in the UK, with...
Chinese University of Hong Kong
The Department of Ophthalmology & Visual Sciences (CUHK DOVS) of the Chinese University of Hong Kong (CUHK) was the first academic ophthalmology depar...